Large scale clinical trial of hepatitis B vaccine in Chongqing today volume trading

NetEase Finance August 19 August 6 Chongqing Beer disclosed its hepatitis B vaccine research progress.　　The bulletin said that the "therapeutic (synthetic peptide) hepatitis B vaccine for the treatment of chronic hepatitis B is a multicenter and safe centre for the Central Laboratory (Group leader Unit) of the People's Hospital of Peking University, randomized, double-blind, placebo-controlled phase II clinical trials are being conducted in clinical hospitals according to clinical trial protocols.　　A few days, Chongqing beer stock price climbed steadily, today opened a large, after trading, trading volume and turnover rate significantly enlarged. After Carlsberg's arrival in Chongqing beer, Carlsberg said that Jia Chen is an important part of the beer business in Chongqing.　　After becoming the biggest shareholder of Chongqing Beer, Carlsberg will strive to keep the stability of the equity structure of the company, and devote itself to the development and growth of Chongqing beer in order to realize the maximum value of the whole shareholder. Societe Generale, the latest research report, Jia Chen Biological treatment of hepatitis B vaccine research, is now in the clinical Phase II, the progress is progressing smoothly. In addition to the center group (360 cases), Zhejiang University Center group (376 cases) has also been activated. The safety and efficacy of therapeutic hepatitis B vaccine will be fully validated in future clinical trials. Carlsberg's acquisition of 12.25% per cent of the company at a price of 40.22 yuan/share indicates that Carlsberg is bullish on the company's strategic value.　　Carlsberg executives also said that the best biological vaccine business to give higher expectations. Amendments to the Constitution, involving the changes in the stock rights of the Jia-Chen as a special resolution of the statute of limitations set for December 31, 2015 before. Societe Generale is expected to see from the current clinical progress, the treatment of hepatitis B vaccine to obtain a new drug certificate or complete three period of clinical, time should be before December 31, 2015.